The aims of this research to prove that repeated exposure of artemisinin can cause genes Plasmodium falciparum of strains 2300 in vitro.
Introduction
Development of Plasmodium falciparum resistance to antimalaria drugs and decreased efficacy of artemisinin and its derivatives cause malaria treatment to become increasingly difficult [1] . This has become one of the foremost health problems in the world because there is no new drug to substitute for artemisinin. Prevention of artemisinin resistance should be a top priority throughout the world. Plasmodium falciparum resistance to artemisinin can happen because it is influenced by a number of factors, viz.
evolution of parasites to survive drug administration and environmental changes, such as nutrient limitation, toxic compounds and temperature that impose new selective and trigger selection of adaptive genetic variants [2, 3] . In the former situation, there is a change in parasite's lifecycle through retardation of growth at the early ring stage and mutations in certain genes [4] [5] [6] .
For instance, resistance to artemisinin has been attributed to mutations in Plasmodium Falciparum adenine triphosphatase 6 gene (pfatpase6) [4, 7] . Variant Pfatpase6, e.g.L263E, E431K, A623E and S769N, have been linked to an increased 50% inhibitory concentrations (IC 50 s) of artemether against Plasmodium falciparum growth in culture [8] . Pfatpase6 variant I89T was found inisolates from Thailand [9] . Variant H243Y from Central Africa and silent T2694A mutation from SaoTome and Principe [10] . Thirtythree single nucleotide polymorphisms (SNPs) also were found in 39%, 29% and 7% of P. falciparum isolates from East and West Africa resulting in pfatpase6 mutations E431K, N569K and A630S [11] . In Iran all Plamodium falciparum isolates exposed artemisinin (ACT) as fist line antimalarial therapy for four years contained mutations L263E and A623E whereas 23% of those not exposed to the drug contained E431K mutation in Sistan and Baluchistan province, so reported that 2.6% of Plasmodium falciparum isolates are resistant to artesunate and all contain pfatpase6 S769N mutation [12] .
Although the mechanism of falciparum resistance to artemisinin remains under investigation Most important molecular surveillance of artemisinin resistance based on multi genetic markers could be more informative than relying on any one particular molecular marker [13] . it is believed that the artemisinin resistance occurs because of mutations in pfcrt, pfmdr1, pfatpase6 and pfk13 [14, 15] .
The occurrence of resistance due to exposure to artemisinin has not to date been investigated in P.falciparum isolates of Indonesian origin. In this study, we investigated the effects of artemisinin exposure to Indonesian chloroquine-resistant Plasmodium falciparum strain 2300. The results of this research can be used as the basis for the DOI 10 .18502/kls.v3i6.1151
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Materials and Methods

Materials
Plasmodium falciparum strain 2300 (chloroquine-resistant) was from Ministry of Health (LITBANGKES) Indonesia and artemisinin from Sigma. parasite DNA extracted using
Invitro gen Kit, five pairs of primer, Purification, precipitation of PCR product and labelling as using Qiagen Kit, In vitro cultivation of Plasmodium falciparum Plasmodium falciparum strain 2300 was grown in culture using the method of Trager and Jensen (1976) [16] . The parasites were synchronized at ring stage with 5% sorbitol treatment that selectively kill all late parasite stages. Culture were followed by standard conditions for 48 h [17] . Parasite growth was monitored by measuring parasitemia of Giemsa-stained thin blood smears after 48 hours until proportion 5% of ring growth [18, 19] . IC 50 value (concentration required to inhibit growth by 50%) of artemisinin against Plasmodium.falciparum strain 2300 growth in culture was determined by adding 
Exposure to artemisinin
For each treatment, 0.5 µl RBC (hematocrit 15%) plus 1µl of infected RBC (>5% parasitemia) were added to 1350 µl of culture medium containing 150 µl artemisinin corresponding to IC 50 concentration. Control sample did not contain the drug. Parasite suspensions were cultured as described above for 48 hours, washed twice with complete medium and cultured as before. First artemisinin exposure (PO1) using IC 50 values (10 
PCR amplification and sequencing of pfatpase6
Parasite DNA was isolted using a commercial kit (Invitrogen). Primers employed in PCR amplification of sequences containing codons suspected of frequent mutations associated with artemisinin resistance are listed in Table 1 
Results
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Artemisinin exposure on Plasmodium falciparum 2300 pfatpase6 sequence
Following exposure to artemisinin, five regions in Plasmodium falciparum 2300 pfatpase6 exons 1 and 2 were PCR amplified and sequenced. These regions contained codons of 10 pfatpase6 amino acids, namely, I89,L263, E431,N460, N465,A623,N683, S769, I898, and C1031, commonly mutated in artemisinin-resistant Plasmodium falciparum. As expected, amplicon sizes remained unchanged from artemisinin-untreated control, despite increase in IC 50 values (Fig 1) . 
Discussion
The Asia, 3 Americans and 2 Oceania), which found 44 SNPs in pfatpase6 genes with a mutation in some codons variations. The prevalence of these SNPs was associated with decreased sensitivity of Plasmodium falciparum to artemisinin. Polymorphism in 87 isolates of Plasmodium falciparum from Niger also found 6 SNPs in the codon of D537D pfatpase6 gene, namely, K561N, N569K, A630S, G639D, K716R, which were used to test the efficacy of artemisinin monitoring [24] .
Analysis of genetic diversity of pfatpase6 of 862 isolates of Plasmodium falciparum in 19 populations from Asia, Africa, South America and Oceania were 71 SNPs identified in the 106 nucleotide haplotypes with a specific mutation on every continent, and the frequency was below 5%. The discovery of SNPs is high enough on the isolates of Plasmodium, after molecular evolution analysis results did not find significant changes VMIC 2017 in pfatpase6 gene in all populations, so that the pfatpase6 gene is still appropriate as a marker for monitoring artemisinin resistance against Plasmodium falciparum [25] .
Mutations in amino acids may alter the conformity of the drug binding site and could potentially lead to decreased sensitivity to artemisinin. The pfatpase6 gene is the target of artemisin in compounds in Plasmodium falciparum. There was a relationship between the pfatpase6 S769N substitution and improvement of artemether in vitro
IC 50 values in isolates from French Guiana 769 residue located in the N cytoplasmic domain (nucleotide binding) that is close to the important conserved area are needed for the development of the ATPase cycle, the bond and the release of calcium that can affect the S769N mutation in a conformational change [8] .
In the transgenic parasites laboratory, the changes in artemisinin sensitivity are associated with mutations in relatively small L263E about 10-20% which gives impact for Plasmodium species, so that these modification scan alter the adjustment of
Plasmodium that can affect sensitivity to artemisinin [28] .
The same study conducted on clinical isolates in Senegal found that the combination of two mutations E431K and A623E are indicating an increase in the IC 50 value, so that a point mutation can be used for molecular monitoring of artemisinin derivatives in vitro continuous surveillance [8] . genes Plasmodium falciparum of strains 2300 in vitro.
